cyrilzakka/clinical-trials huggingface dataset:
Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

Keloid is chronic skin conditions that results in formation of tumor like growths on the skin. Despite its benign nature, keloid can cause severe aesthetic and, in some cases, functional problem which negatively impacts person's quality of life.

Keloids do not regress on their own and results of most available treatments such as surgery, injecting keloids with steroids, chemotherapy injections, or even radiation therapy, have mostly proven disappointing.

Some laboratory studies have shown that there is excessive amount of a protein called "vascular endothelial growth factor (VEGF)" in keloid tissue. This may play role in the formation and evolution of keloid.

Bevacizumab is a drug that works by targeting vascular endothelial growth factor (VEGF) which helps new blood vessels form. Without new blood vessels, the growth of the keloid may be slowed

Based on presence of excess amount of VEGF in keloid tissue, we hypothesize that bevacizumab will be effective in treatment of keloids. This exploratory clinical trial is to confirm or reject this hypothesis.

Sixty Eligible patients will be enrolled in the study. This will be a two stage design trial.

In stage I of the trial, 21 patients will be treated with intralesional bevacizumab. Keloids that fail to respond to 4 injections will not be treated any longer with bevacizumab and all such patients will be removed from the trial.

If 5 or more patients show some degree of objective response to treatment in at least one treated keloid, the trial will continue to enroll another 45 patients to a total of 66 patients, otherwise, the trial will stop in its entirety.

Eligibility Criteria:
Inclusion Criteria:

1. Clinical Diagnosis of a flat keloid.
2. Age 18 to 50
3. A signed informed consent document (ICD)
4. Able and willing to receive bevacizumab

Women of child-bearing potential must have a negative pregnancy test during screening. The effects of bevacizumab on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

Exclusion Criteria:

1. Pedunculated Keloid
2. Diastolic Blood pressure of 90 mm Hg or above
3. History of any degree of Hypertension, even medically controlled hypertension
4. History of any form of cardiovascular disease or stroke
5. History of any form of thromboembolic event
6. History of renal dysfunction or proteinuria
7. History of recent (past 12 month) or planned (next 3 months) major surgery,
8. Men and women who plan to have children within 6 months of their last treatment
9. Psychological Illness that may result in non compliance with treatment
10. Pregnancy and Breast Feeding
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)

The purpose of this study is to compare the long-term effectiveness of acupuncture versus massage in people living with advanced cancer. The study will test how the two approaches compare in helping people with pain and its related symptoms and improving quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years or older
* Having a diagnosis of the following: stage III or IV lung cancer; any stage pancreatic cancer; unresectable cholangiocarcinoma; unresectable liver cancer; unresectable ampullary or peri-ampullary cancer or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer; stage IV genitourinary cancer; stage III or IV sarcoma; stage IV melanoma; stage III or IV head/neck cancer; stage IV endocrine cancer; or hematological malignancies (lymphoma, myeloma, and leukemia)
* Be ambulatory (Karnofsky functional score of ≥ 60)
* Having musculoskeletal pain, defined as regional (joints, extremities, back, neck) or more generalized (fibromyalgia or chronic widespread pain); Patients with a neuropathic component to their pain that involves the extremities or back will be eligible.
* Having musculoskeletal pain for at least 1 month
* Having had pain for at least 15 days in the preceding 30 days
* Having a pain rating of 4 or greater in worst pain on a 0-10 numerical rating scale in the preceding week
* Having an expected prognosis of greater than six months as judged by the treating oncologist or study physician

Exclusion Criteria:

* Having a platelet count \<15,000
* Cognitive impairment precluding response to study assessments
* Unwilling to accept random assignment
* Unwilling to commit to the 26-week study time period
* Have non-musculoskeletal pain syndromes (headache, facial pain, chest pain, visceral abdominal pain) if these are the sole source of pain but can be present as co-morbid conditions as long as a patient has a primary musculoskeletal pain condition defined as above.
Adherence to Polypharmacy in Patients With Opioid Substitution Therapy Using Electronics

Electronic dispensers for polypharmacy are used in home care to assist patients with their medication management and to improve adherence. Opioid dependent patients with substitution therapy often exhibit multiple risk factors for non-adherence. The increase of both the age and associated comorbidities in this population demand for innovative solutions to optimize medication management. The investigators developed a novel medication supply model with an automated electronic medication dispenser to simultaneously assist opioid dependent patients with their medication and objectively monitor their adherence. This study aims to demonstrate the feasibility of the new supply model.


Eligibility Criteria:
Inclusion Criteria:

* written informed consent given
* reading and writing skills in German
* Stable housing situation in the canton of Basel-City and adjacent communities
* Accessibility by phone
* Minimum duration in opioid substitution treatment for 2 months
* Polypharmacy (\> 3 solid oral medications)
* Routine monitoring of clinical parameters less than 1 week before inclusion or agreed within 1 week from inclusion
* Insured with Swiss health insurance

Exclusion Criteria:

* opioid substitution treatment with Diacetylmorphine
* \> 2 drugs, which can not be packaged in pouches (eg liquids)
Immuno-effect of Tα1 for Stage I NSCLC

To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).


Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed stage I (per AJCC 8th edition) invasive NSCLC
* Resectable tumor
* undergoing lobectomy and systemic lymph node dessection
* Without a previous history of malignant tumors or other concurrent malignancies
* Naïve to any anticancer therapies or other immunostimulatory agents
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1, with cardiac, pulmonary, hepatic, cerebral, and renal functions capable of withstanding surgery
* Aged ≥18 years and ≤75 years
* Having signed written informed consent and capable of adhering to the visit schedule and related procedures outlined in the study protocol

Exclusion Criteria:

* With a pathologically confirmed non-invasive NSCLC, including preinvasive lesions, small cell lung cancer, and benign lesions
* Post-diagnostic use of immunosuppressive medications or other immunostimulatory agents
* With known or suspected active autoimmune disease
* Allergic to thymopeptides
* With other uncontrolled serious illnesses or having acute or chronic conditions that may confound test outcomes, including active severe clinical infections ( \&gt;NCI-CTCAE grade 2 infection); diagnosed with epilepsy requiring antiepileptic treatment; on renal dialysis; with non-healing wounds, ulcers, or fractures; with a history of arteriovenous thrombotic events, including cerebrovascular accident, deep vein thrombosis, and pulmonary embolism, within six months prior to the first dose
The Medication Experience Study

The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve medication use.


Eligibility Criteria:
Inclusion Criteria:

* Any male or female 18 years or older, filling prescriptions for oral medications for hypertension, high cholesterol, diabetes, or depression at the Downtown Health Plaza, Piedmont Plaza, or Cancer Center Pharmacies.

Exclusion Criteria:

* Inability to complete Internet surveys due to inadequate Internet access, not understanding a survey written in English, or lack of computer skills.
* Patient does not intend to continue using the same WFBMC-affiliated pharmacy for the next 12 months.
Mechanism Of Stent Thrombosis (MOST) Study

This study is designed to assess the pathophysiology of ST by studying the main procedural and anatomical factors involved in the genesis of ST such as those related to stent and the vascular wall, as well as to the individual platelet residual reactivity.


Eligibility Criteria:
Inclusion Criteria:

* previous PCI with bare metal stent (BMS) or drug eluting stent (DES) and a definite subacute coronary ST
* previous PCI with DES and a definite late or very late coronary ST

Exclusion Criteria:

* Development of ST within 72 hours of stent implantation (acute and early subacute ST).
* Late and very late ST of BMS.
* Absence of informed consent.
* Age less than 18 years.
* Creatinine values greater than 2.5 g/dl (this is to avoid the negative effects related to the contrast medium necessary to perform the OCT evaluation).
Safety and Efficacy Study of a Eye Drop for Eye Allergy

The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.


Eligibility Criteria:
Inclusion Criteria:

* At least 10 years of age
* positive history of ocular allergies
* positive skin test reaction to allergens.

Exclusion Criteria:

* known allergy, contraindication, or sensitivities to the use of any of the study medication(s) or their components
* ocular surgical intervention within three (3) months prior to visit 1 or during the study
* known history of retinal detachment, diabetic retinopathy, or progressive retinal disease, or glaucoma
* any other significant illness
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

The purpose of this study is to evaluate the efficacy and safety of sintilimab+ IBI310 for EBV-Positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.


Eligibility Criteria:
Inclusion Criteria:

* Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic gastric or GEJ malignant tumor (including squamous carcinoma, adenocarcinoma, Signet-ring cell carcinoma).
* Confirmed EBV positive determined by in situ hybridization (ISH), analyzed with tumor tissue sample, either from a previous surgery or biopsy , within last 6 months
* Male or Female at least 18 years of age
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Has adequate organ function.
* Expected survival\>=12 weeks
* Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test at the timing of enrollment.
* Participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 6 months after the last dose of study medication.

Applied to Arms 1: Has histologically confirmed gastric/GEJ malignant tumor, and were regarded as having clinical stage T3-T4aN0M0 or T2～4aN+M0

Applied to Arms 2: Had no prior systemic treatment for metastatic disease.

Applied to Arms 3: Received ≥1 prior systemic treatment for metastatic disease.

Exclusion Criteria:

* Has received prior therapy with an anti-programmed death (PD)-1, antiPD-L1, anti-PD L2, anti-CTLA-4 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
* Is currently participating in and receiving study therapy ,except those in the survival follow up period of an investigational agent study or non-interventional study .
* Received systemic treatment with corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 4 weeks of first dose. Inhaled or topical steroids ,adrenal replacement steroid doses and steroid of prevention allergic reaction of i.v. contrast agent are permitted in the absence of active autoimmune disease.
* Received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.
* Has had major surgery (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to first dose of study medication, or anticipation of the need for major surgery during the course of study treatment
The Effect of Personal Activity Intelligence Versus 10,000 Steps Daily on Cardiorespiratory Fitness

A high physical fitness can prevent cardiovascular disease. Which form of exercise training is efficient at improving fitness is well known. The challenge is to get people to do it. Personal activity intelligence (PAI) is an algorithm developed for this challenge. It gives a score that tells the users whether they are active enough to achieve the maximum health benefit of exercise based on their heart rate. It has been shown that people who obtain 100 PAI a week have less cardiovascular disease, but intervention studies showing that PAI can improve physical fitness are so far lacking.

Step counters have received a lot of attention and 10 000 steps a day is a common recommendation, but little is known about the physiological adaptations to this intervention.

This study will compare the effect of physical activity with a value of 100 PAI points a week with 10 000 steps a day in healthy, but overweight (body mass index \> 25) participants between 30 and 50 years of age.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index (BMI) \> 25
* Low physical activity (less than 50 PAI points calculated from a questionnaire)

Exclusion Criteria:

* Cancer diagnosis
* Cardiac arrhythmia
* Angina
* Previous myocardial infarction
* lung disease
* heart disease
* uncontrolled hypertension
* kidney disease
* orthopedic or neurological limitations
* planned surgery during the intervention
* participation in other research studies conflicting with the current study
Turkish Version of Fear of Falling Avoidance Behavior Questionnaire

This study is planned to translate the Fear of Falling Avoidance Behaviour Questionnaire (FFABQ) into Turkish and to assess the psychometric properties (validity, reliability, responsiveness, floor and ceiling effect) of this Turkish version.

The permission for the Turkish version was received by Landers. The translation will be made according to Beaton et al. guidelines. The internal reliability of the FFABQ Türkish version will be assessed using Cronbach's alpha, and item analyses will be conducted by examining the effect on Cronbach's alpha of excluding each of the six FOG-Q items individually. The test-retest reliability will be assessed using intraclass correlation coefficient (ICC).

Convergent validity will be evaluated by means of Spearman rank correlation coefficient (rs). In this section will be determined the correlation between the Activities-specific Balance Confidence Scale and visual analog scale for fear of falling.

Eligibility Criteria:
Inclusion Criteria:

* having good cognitive functions (Standardized Mini Mental Test score of 24 and above)
* To be able to live independently in the community,
* to voluntarily participate

Exclusion Criteria:

* The use of drugs that may affect balance
* Polypharmacy status
* Having serious musculoskeletal or neurological disorders,
* Lower or upper limb amputation that may affect balance.
Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

To assess the safety and efficacy of third-line and above therapy of patients with local advanced or metastatic non-small cell lung cancer (NSCLC) with combined treatment with launched recombinant humanized anti-PD-1 monoclonal antibody and Donafenib Tosilate

Donafenib has a multi-target and dual anti-tumor effect, similar to sorafenib toluene sulfonate, and its effect is similar to that of sorafenib toluene sulfonate. Donafenib has the potential to be effective in the treatment of cancer, including advanced non-small cell lung cancer. PD-1 inhibitor has become a new therapy for advanced non-small cell lung cancer because of its strong specificity, definite efficacy, small side effects and long time of tumor control.

This is a single-center, open, single-arm, exploratory phase Ib trial. There were two dosages of donafenib (100mg qd and 100mg bid, respectively). Three to six subjects were enrolled in the dosages of 100mg qd. The investigators determined that the dosages of 100mg bid were well tolerated

Eligibility Criteria:
Inclusion Criteria:

1、18 years age or older ,male or female

2、Histologically or cytologically confirmed diagnosis of local advanced or metastatic NSCLC

3、Previously received with two or more systemic Antitumor treatments (Chemotherapy or targeted therapy). Chemotherapy treatments must include a two-drug regimen containing platinum, patients with EGFR TKI drug resistance and unknow T790M mutation, after AZD9291 treatment patients with T790M mutation could be enrolled

4、At least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation

5、Asymptomatic patients with uncontrolled brain metastases or brain metastases involving the pia mater

6、Patients must have recovered from all toxicities related to prior anticancer therapies to ≤ 2 (CTCAE v5.0). AE of Neurology must be ≤ 1

7、Life expectancy ≥ 12 weeks

8、ECOG performance status 0-1

Exclusion Criteria:

1. Small cell lung cancer (including small lung cancer mixed with non-small cell lung cancer)
2. Patients at risk of bleeding treated with antiangiogenic drugs
3. Subjects who are using immunosuppressive agents, or systemic, or absorbable topical hormone therapy for immunosuppressive purposes (dose \>10mg/ dprednisone or other therapeutic hormones) and who continue to use it for 2 weeks prior to enrollment
4. Patients with active, known or suspected autoimmune diseases, including tuberculosis, HIV infection, active hepatitis, etc.
5. Patients with previous and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, severe impairment of lung function, etc
6. Women who are pregnant or lactating, or who are unwilling to use contraception during the trial
Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity

The study aims to evaluate if a GERD treatment programme, in accordance with current regional recommendations, in a company health care setting, has an impact on health related quality of life (HRQoL), symptoms, and productivity in GERD patients.


Eligibility Criteria:
Inclusion Criteria:

* Female and/or male aged \> 18 years
* Diagnosis of GERD confirmed
* Prescription of GERD treatment or already receiving GERD treatment

Exclusion Criteria:

* Any symptom suggesting a need for further investigation
* Previous participation in the present study
* Current participation in a clinical study or participation in a clinical study during the last 30 days
Evaluation of Breast Reduction Techniques

The purpose of this study is to retrospectively evaluate breast reduction techniques in terms of complications, functionality, patient satisfaction, and cosmetic outcomes.

A breast reduction is a common operation with a fairly high complication rate as large incision techniques require undermined skin flaps to be closed under tension. This study is evaluation the open incision breast reduction technique to a liposuction assisted breast reduction. This study will evaluate these two breast reduction techniques in terms of complication rates, functionality, patient satisfaction, and cosmetic outcomes. Participants will be asked to complete the BREAST-Q survey regarding their breast reduction postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* Patients who underwent a breast reduction between 2013 and 2019
* All patients who underwent a liposuction assisted or layered skin incision pedicled technique breast reduction.

Exclusion Criteria:

* Patients who underwent additional procedures simultaneously at the time of the breast reduction.
Near-infrared Vision for Microcirculatory Status

The investigators aimed to combine the image of near-infrared vision and machine learning method to evaluate the microcirculatory status of critical ill patients.

The heat distribution of body is determined by the circulatory status. The investigators plan to the near-infrared vision to collect heat distribution information of limbs. Then, the machine learning method will be performed to recognize the subtle differences between images. Due to lack of golden standard of microcirculatory status, indirect parameters (such as lactate clearance, capillary refill time) and clinical outcomes will be recorded to evaluate the performance of maching learning model.

Eligibility Criteria:
Inclusion Criteria:

* Age≥18 years;
* Patients who were transfered to our ICU.

Exclusion Criteria:

* Abnormalities of lower limbs arteries
Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject

The purpose of this study is to determine whether N2O (laughing gas) has an antinociceptive effects in healthy volunteers.

10 healthy volunteers will come twice to the pain medicine unit, at 1 visit they'll get N2O and in the second visit they'll get air as placebo, they won't know what they're getting. During the visit they'll get heat stimulus using QST and will have to report their pain using eVAS (scale from 0 to 100 when 0 is no pain and 100 is the worst pain imagine).

Eligibility Criteria:
Inclusion Criteria:

* 18-50 years old
* women and men
* healthy

Exclusion Criteria:

* smokers
* medication use pregnant woman cardiovascular disease